Evercore ISI lowered the firm’s price target on Cencora (COR) to $360 from $420 and keeps an Outperform rating on the shares. The firm made several price target adjustments and additions to the firm’s Tactical call lists as part of the firm’s healthcare technology and distribution preview for Q1.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COR:
- Cencora to Acquire EyeSouth Retina Business for Expansion
- Cencora signs agreement to acquire EyeSouth Partners’ retina business for $1.1B
- Midday Fly By: Nvidia bullish on AI revenue, MasterCard to acquire BVNK
- Cencora CFO Retirement Announced, Financial Guidance Reaffirmed
- Cencora CFO James Cleary to retire
